Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 601 - 625 of 14536 in total

Acetohexamide

A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Dinutuximab

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Matched Description: … It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the ... constant regions of human IgG1 heavy-chain and kappa light-chain. ... , a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Aflibercept

Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … it was approved by the FDA and EMA in August 2012 and February 2013, respectively. ... composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and ... sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Miltefosine

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of ... It can be administered topically or orally and is only indicated in patients aged 12 years or older. ... first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Becaplermin

Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together...
Approved
Investigational
Matched Description: … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins ... Preparations for Treatment of Wounds and Ulcers …

Cetuximab

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Description: … neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with ... EGFR overexpression has been linked to more advanced disease and poor prognosis. ... cells; it is responsible for regulating epithelial tissue development and homeostasis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Casein

Casein allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Fluids and Secretions ... Diet, Food, and Nutrition ... Amino Acids, Peptides, and Proteins …

Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …

Miglustat

Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now...
Approved
Matched Description: … patients in the European Union, Brazil, and South Korea. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C ... It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Migalastat

Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Paromomycin

An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism …

Ribostamycin

Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Approved
Experimental

Meprednisone

Approved
Investigational
Matched Categories: … Sex Hormones and Insulins …

Methylprednisone

Methylprednisone has been used in trials studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and Acute Lymphocytic Leukemia, among others.
Approved
Investigational
Matched Description: … studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and …

Corticorelin ovine triflutate

Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary...
Approved
Matched Description: … Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the ... If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed ... However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Diiodohydroxyquinoline

Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Bezlotoxumab

Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce the recurrence of C. difficile infection. On November 22, 2016, the Committee for Medicinal Products...
Approved
Investigational
Matched Description: … humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to _Clostridium difficile_ toxin B and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Ltd. and co-developed with Roche and Genentech.[L1015] ... it has the capacity to bind simultaneously to activated Factor IX and Factor X. ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …

Sutimlimab

Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … [A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in ... IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and ... is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Satralizumab

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use ... interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and ... at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Human varicella-zoster immune globulin

Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the...
Approved
Matched Description: … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and ... VariZIG to reduce the disease severity in high-risk patients who lack evidence of immunity to varicella and …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins …

Miglitol

Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the ... glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and …
Matched Categories: … Alimentary Tract and Metabolism …

Trilostane

Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Approved
Investigational
Vet approved
Withdrawn
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Technetium Tc-99m mebrofenin

Technetium Tc 99m Mebrofenin is a diagnostic radiopharmaceutical composed of diisopropyl-iminodiacetic acid (DISIDA) attached to a technetium-99m ion. Following intravenous injection, single photon emission computer tomography (SPECT) imaging of the liver or gallbladder is performed using a gamma camera to detect the gamma rays emitted by the technetium-99m as it...
Approved
Matched Description: … uptake and fast biliary excretion, resulting in improved hepatic imaging. ... More specifically, mebrofenin is taken up into hepatocytes through the action of OATP1B1 and OATP1B3 ... Currently available within a sterile kit, Tc-99m Mebrofenin is indicated for imaging of the liver and …
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hepatic and Reticulo Endothelial System …

Sacituzumab govitecan

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Commission and Health Canada respectively. ... [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 601 - 625 of 14536 in total